The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression.

Nature communications (2019-07-26)
Hélène Lazareth, Carole Henique, Olivia Lenoir, Victor G Puelles, Martin Flamant, Guillaume Bollée, Cécile Fligny, Marine Camus, Lea Guyonnet, Corinne Millien, François Gaillard, Anna Chipont, Blaise Robin, Sylvie Fabrega, Neeraj Dhaun, Eric Camerer, Oliver Kretz, Florian Grahammer, Fabian Braun, Tobias B Huber, Dominique Nochy, Chantal Mandet, Patrick Bruneval, Laurent Mesnard, Eric Thervet, Alexandre Karras, François Le Naour, Eric Rubinstein, Claude Boucheix, Antigoni Alexandrou, Marcus J Moeller, Cédric Bouzigues, Pierre-Louis Tharaux
ABSTRAKT

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here we show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
MISSION® shRNA, Purified DNA
Sigma-Aldrich
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA, Targets no known mammalian genes
Sigma-Aldrich
Anti-FAK Antibody, Upstate®, from rabbit
MISSION® shRNA Product Offerings, Order Custom and Predesigned shRNA